Medical College of Wisconsin
CTSIResearch InformaticsREDCap

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010 Nov 11;116(19):3705-14

Date

07/09/2010

Pubmed ID

20610811

Pubmed Central ID

PMC2981531

DOI

10.1182/blood-2010-04-001230

Scopus ID

2-s2.0-78149474940 (requires institutional sign-in at Scopus site)   110 Citations

Abstract

Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia. Treatment with chemotherapy over the past 3 decades has been palliative. The introduction of therapeutic antibodies has increased the number of treatment options for this disease. Despite this increase, our true understanding of the mechanism of action of antibody therapy in CLL remains limited. Rituximab, a CD20 antibody, is currently widely used in combination-based strategies for both previously untreated symptomatic CLL and as salvage therapy. Recent data suggest that the addition of rituximab to fludarabine with or without cyclophosphamide prolongs survival in younger patients with CLL. Other improved CD20 antibodies with promising clinical activity, including ofatumumab and GA-101, are coming forward. Alemtuzumab, a CD52 antibody, likewise has demonstrated benefit in both symptomatic, previously untreated CLL and in patients with relapsed disease but has less selectivity. Development of other therapeutic antibodies targeting alternative B-cell-specific antigens in CLL has been less successful, although many promising candidate antibodies and/or small modular immune pharmaceuticals (SMIPs) are coming forward. In addition, recent efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative non-chemotherapy-based treatment approaches.

Author List

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC

Author

Samantha M. Jaglowski BS, MD, MPH, MBA Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antineoplastic Agents
Autoimmune Diseases
Clinical Trials as Topic
Combined Modality Therapy
Humans
Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Models, Immunological
Rituximab